The Race to Lead in Life Sciences Innovation: Lessons from Global Benchmarks (L.E.K. Consulting)

Summary

• Leading life sciences ecosystems have shaped global healthcare for decades, and both established and emerging hubs are now accelerating.p.2
• Legacy leaders such as Boston, the Bay Area and the United Kingdom have long set the benchmark, while rising hubs across Asia and the Middle East are shaping their own models.p.2
• L.E.K. Consulting identified five pillars of a thriving innovation ecosystem: public funding, capital markets, operational enablers, human and network capital, and commercial.p.3
• Global leaders show balanced strength across all pillars, while emerging ecosystems face structural gaps in late-stage capital, global-facing talent and scalable exit pathways.p.4
• Shanghai has advanced rapidly but remains heavily government-driven, with commercial efforts often domestically focused.p.4

Key insights

1. Innovation in life sciences is becoming a strategic growth engine across regions.p.2
2. Countries are racing to build ecosystems that can translate scientific discovery into global impact.p.2
3. The benchmark covers indicators such as startup funding, VC deal value in life sciences, biotech exits, approval time for clinical trials and pharma market size.p.3
4. Boston, the Bay Area and the UK were benchmarked against Shanghai, Singapore and South Korea.p.4
5. Singapore has a highly structured innovation ecosystem but lacks private capital leadership, a robust exit environment and globally experienced talent.p.4
6. South Korea benefits from a strong R&D base and top-tier local clinical networks but lacks experienced biotech founders and global BD capabilities, and has limited late-stage capital.p.4